Analyst picks & changes

Company

Bank

Analyst

Coverage

Opinion

Wk chg

8/8 cls

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)

Roth Capital Partners

Scott Henry

Downgrade

Neutral (from buy)

-16%

$4.04

Henry also lowered his target to $5.50 from $10, saying the revenue ramp for Adasuve loxapine appears "slower than originally targeted." He lowered his U.S. Adasuve end-user revenue forecasts to less than $1M from $17M in 2014; to $31M from $94M in 2015; and to $82M from $156M in 2016. He continues to project peak sales of over $200M. The product is approved to treat acute agitation in adults with schizophrenia or bipolar disorder in the U.S., where Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has rights.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

William Blair

Y. Katherine Xu

Upgrade

Outperform (from market perform)

16%

$10.84